모수네투주맙 및 폴라투주맙 베도틴을 이용한 CD20 양성 증식성 장애의 치료 방법

본원 발명은 모수네투주맙 및 폴라투주맙 베도틴을 병용 투여하여 CD20 양성 세포 증식성 장애를 겪는 개체의 치료에 관련된다. The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disor...

Full description

Saved in:
Bibliographic Details
Main Authors OKI YASUHIRO, O'HEAR CAROL ELAINE, TO IRIS TRANTHUYNGAN
Format Patent
LanguageKorean
Published 16.01.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:본원 발명은 모수네투주맙 및 폴라투주맙 베도틴을 병용 투여하여 CD20 양성 세포 증식성 장애를 겪는 개체의 치료에 관련된다. The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
Bibliography:Application Number: KR20237039989